Compounds > 4-n-pyrrolidinylazobenzene
Page last updated: 2024-11-07

4-n-pyrrolidinylazobenzene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-N-pyrrolidinylazobenzene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114785
SCHEMBL ID7764536
SCHEMBL ID10343353
MeSH IDM0099756

Synonyms (13)

Synonym
1-(p-(phenylazo)phenyl)pyrrolidine
4-n-pyrrolidinylazobenzene
brn 0220377
1-(4-(phenylazo)phenyl)pyrrolidine
pyrrolidine, 1-(4-(phenylazo)phenyl)-
pyrrolidine, 1-(p-(phenylazo)phenyl)-
phenyl-(4-pyrrolidin-1-ylphenyl)diazene
5-20-01-00446 (beilstein handbook reference)
10282-34-5
SCHEMBL7764536
SCHEMBL10343353
DTXSID101037742
pyrrolidine, 1-[4-(2-phenyldiazenyl)phenyl]-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methyldimethylaminoazobenzene
Methyldimethylaminoazobenzene: A very potent liver carcinogen.. 3-methyl-4'-dimethylaminoazobenzene : A member of the class of azobenzenes that is azobenzene in which one of the phenyl groups is substituted at position 3 by a methyl group, while the other is substituted at position 4 by a dimethylamino group. It is a potent liver carcinogen.		2.3720
p-dimethylaminoazobenzene
p-Dimethylaminoazobenzene: A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound may reasonably be anticipated to be a carcinogen. (Merck, 11th ed)		2.6530azobenzenes
thiazoles
[no description available]		1.96101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
n,n-dimethyl-4-(6-benzothiazolylazo)aniline
N,N-dimethyl-4-(6-benzothiazolylazo)aniline: do not confuse with 5-isomer (RN: 18463-90-6) also given this name in 9CI; structure		1.9610
5-dimethylaminophenylazoindazole
5-dimethylaminophenylazoindazole: noncarcinogenic bacterial mutagen DAB analog; structure given in first source		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Liver
[description not available]		01.9510
Experimental Neoplasms
[description not available]		01.9510
Liver Neoplasms
Tumors or cancer of the LIVER.		01.9510
Experimental Hepatoma
[description not available]		02.3720
Condition, Preneoplastic
[description not available]		01.9610
Cocarcinogenesis
The combination of two or more different factors in the production of cancer.		01.9610
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		01.9610